K M Beusterien

Summary

Affiliation: Covance Laboratories
Country: USA

Publications

  1. ncbi request reprint Health-related quality of life effects of modafinil for treatment of narcolepsy
    K M Beusterien
    Covance Health Economics and Outcomes Services, Inc, Washington, DC 20005 3934, USA
    Sleep 22:757-65. 1999
  2. ncbi request reprint The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients
    K M Beusterien
    Covance Health Economics and Outcomes Services Inc, Washington, DC 20005, USA
    Support Care Cancer 9:169-76. 2001
  3. ncbi request reprint Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS
    S J Ackerman
    Covance Health Economics and Outcomes Services Inc, Washington, DC, USA
    Pharmacoeconomics 15:179-95. 1999

Collaborators

  • S J Ackerman
  • E M Sullivan
  • D L Patrick
  • H M Natter
  • D F Gelinas

Detail Information

Publications3

  1. ncbi request reprint Health-related quality of life effects of modafinil for treatment of narcolepsy
    K M Beusterien
    Covance Health Economics and Outcomes Services, Inc, Washington, DC 20005 3934, USA
    Sleep 22:757-65. 1999
    ..To evaluate the burden of illness of narcolepsy and assess the health-related quality-of-life (HQL) effects of oral modafinil, a wake-promoting therapy for excessive daytime sleepiness associated with narcolepsy...
  2. ncbi request reprint The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients
    K M Beusterien
    Covance Health Economics and Outcomes Services Inc, Washington, DC 20005, USA
    Support Care Cancer 9:169-76. 2001
    ..We conclude that pamidronate therapy may be associated with less medical resource utilization, particularly among patients hospitalized for bone-related conditions...
  3. ncbi request reprint Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS
    S J Ackerman
    Covance Health Economics and Outcomes Services Inc, Washington, DC, USA
    Pharmacoeconomics 15:179-95. 1999
    ..Recombinant human insulin-like growth factor I (rhIGF-I) has been shown to be useful in treating ALS. The purpose of this study was to examine the cost effectiveness of rhIGF-I therapy in patients who have ALS...